Advanced search
Publication Cover
Expert Review of Clinical Pharmacology Volume 5, 2012 - Issue 5
Submit an article Journal homepage
113
Views
8
CrossRef citations to date
0
Altmetric
Review

Safety of pharmacoenhancers for HIV therapy

Nils von Hentig HIVCENTER, Medical Department II, Hospital of the J. W. Goethe-University, Frankfurt, Germany. [email protected]
&
Annette Haberl HIVCENTER, Medical Department II, Hospital of the J. W. Goethe-University, Frankfurt, Germany
Pages 557-568 | Published online: 10 Jan 2014

References

  • Lee L, Karon J, Selik R, Neal J, Fleming P. Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984–1997. JAMA 285, 1308–1315 (1998).
  • Mocroft A, Ledergerber B, Katlama C et al .; EuroSIDA study group. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 362(9377), 22–29 (2003).
  • Collot-Teixeira S, De Lorenzo F, Waters L et al. Impact of different low-dose ritonavir regimens on lipids, CD36, and adipophilin expression. Clin. Pharmacol. Ther. 85(4), 375–378 (2009).
  • Carr A. Cardiovascular risk factors in HIV-infected patients. J. Acquir. Immune Defic. Syndr. 34(Suppl. 1), S73–S78 (2003).
  • Sax PE, Kumar P. Tolerability and safety of HIV protease inhibitors in adults. J. Acquir. Immune Defic. Syndr. 37(1), 1111–1124 (2004).
  • Friis-Møller N, Reiss P, Sabin CA et al . DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N. Engl. J. Med. 356(17), 1723–1735 (2007).
  • Morgello S, Mahboob R, Yakoushina T, Khan S, Hague K. Autopsy findings in a human immunodeficiency virus-infected population over 2 decades: influences of gender, ethnicity, risk factors, and time. Arch. Pathol. Lab. Med. 126(2), 182–190 (2002).
  • Friis-Møller N, Sabin CA, Weber R et al . Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N. Engl. J. Med. 349(21), 1993–2003 (2003).
  • Perronne C. Antiviral hepatitis and antiretroviral drug interactions. J. Hepatol. 44(1 Suppl), S119–S125 (2006).
  • Wilby KJ, Greanya ED, Ford JA, Yoshida EM, Partovi N. A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients. Ann. Hepatol. 11(2), 179–185 (2012).
  • Vachon ML, Dieterich DT. The HIV/HCV-coinfected patient and new treatment options. Clin. Liver Dis. 15(3), 585–596 (2011).
  • Soriano V, Sherman KE, Rockstroh J et al. Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-co-infected patients. AIDS 25(18), 2197–2208 (2011).
  • Seden K, Back D, Khoo S. New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals. J. Antimicrob. Chemother. 65(6), 1079–1085 (2010).
  • Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin. Pharmacokinet. 35(4), 275–291 (1998).
  • Gallant JE. Protease-inhibitor boosting in the treatment-experienced patient. AIDS Rev. 6(4), 226–233 (2004).
  • Cohen C, Elion R, Ruane P et al. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS 25(6), F7–F12 (2011).
  • Elion R, Cohen C, Gathe J et al . GS-US-216-0105 Study Team. Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection. AIDS 25(15), 1881–1886 (2011).
  • Roberts NA, Martin JA, Kinchington D et al. Rational design of peptide-based HIV proteinase inhibitors. Science 248(4953), 358–361 (1990).
  • Danner SA, Carr A, Leonard JM et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N. Engl. J. Med. 333(23), 1528–1533 (1995).
  • Markowitz M, Saag M, Powderly WG et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N. Engl. J. Med. 333(23), 1534–1539 (1995).
  • Lorenzi P, Yerly S, Abderrakim K et al. Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir. Swiss HIV Cohort Study. AIDS 11(12), F95–F99 (1997).
  • Merry C, Barry MG, Mulcahy F et al. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 11(4), F29–F33 (1997).
  • Hoetelmans RM, Meenhorst PL, Mulder JW, Burger DM, Koks CH, Beijnen JH. Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir. Pharm. World Sci. 19(4), 159–175 (1997).
  • Hsu A, Granneman GR, Cao G et al. Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrob. Agents Chemother. 42(11), 2784–2791 (1998).
  • Sham HL, Kempf DJ, Molla A et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob. Agents Chemother. 42(12), 3218–3224 (1998).
  • Kaletra®, prescribing information. Abbott Laboratories, IL, USA (2003).
  • Kempf DJ, Marsh KC, Denissen JF et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl Acad. Sci. USA 92(7), 2484–2488 (1995).
  • Cooper CL, van Heeswijk RP, Gallicano K, Cameron DW. A review of low-dose ritonavir in protease inhibitor combination therapy. Clin. Infect. Dis. 36(12), 1585–1592 (2003).
  • Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br. J. Clin. Pharmacol. 44(2), 190–194 (1997).
  • Hsu A, Granneman GR, Witt G et al. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob. Agents Chemother. 41(5), 898–905 (1997).
  • Granfors MT, Wang JS, Kajosaari LI, Laitila J, Neuvonen PJ, Backman JT. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin. Pharmacol. Toxicol. 98(1), 79–85 (2006).
  • Kumar GN, Dykstra J, Roberts EM et al. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: a positive drug–drug interaction. Drug Metab. Dispos. 27(8), 902–908 (1999).
  • Kaletra® Fachinformation. EU/1/01/172/004, EU/1/01/172/005, EU/1/01/172/007. Abbott Laboratories Ltd., Berkshire, UK (2010).
  • von Hentig N, Lötsch J. Cytochrome P450 3A inhibition by atazanavir and ritonavir, but not demography or drug formulation, influences saquinavir population pharmacokinetics in human immunodeficiency virus type 1-infected adults. Antimicrob. Agents Chemother. 53(8), 3524–3527 (2009).
  • Crommentuyn KM, Kappelhoff BS, Mulder JW et al. Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients. Br. J. Clin. Pharmacol. 60(4), 378–389 (2005).
  • Solas C, Poizot-Martin I, Drogoul MP et al. Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor. Br. J. Clin. Pharmacol. 57(4), 436–440 (2004).
  • Hsu A, Isaacson J, Brun S et al. Pharmacokinetic-pharmacodynamic analysis of lopinavir–ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 47(1), 350–359 (2003).
  • Kilby JM, Sfakianos G, Gizzi N et al. Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults. Antimicrob. Agents Chemother. 44(10), 2672–2678 (2000).
  • European Medicines Agency. Doc. Ref.: EMA/793683/2009 EMEA/H/C/127 (2009).
  • von Hentig N. Lopinavir/ritonavir: appraisal of its use in HIV therapy. Drugs Today (Barc.) 43, 221–247 (2007).
  • von Hentig N. Atazanavir/ritonavir: a review of its use in HIV therapy. Drugs Today 44(2), 103–132 (2008).
  • Norvir®, prescribing information. Abbott Laboratories, IL, USA (2011).
  • German P, Lui C, Warren D et al. Effect of cobicistat on glomerular filtration rate (GFR) in subjects with normal and impaired renal function. Presented at: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2011. Chicago, IL, USA, 17–20 September 2011.
  • Elion R, Gathe J, Rashbaum B. The single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (EVG/COBI/FTC/TDF; “QUAD”) maintains a high rate of virologic suppression and cobicistat (COBI) is an effective pharmacoenhancer through 48 weeks. Presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2010. Boston, MA, USA, 12–15 September 2010.
  • German P, Warren D, West S, Hui J, Kearney BP. Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV. J. Acquir. Immune Defic. Syndr. 55(3), 323–329 (2010).
  • Sax P, DeJesus E, Mills A et al. Elvitegravir/cobicistat/emtricitabine/tenofovir (QUAD) has non-inferior efficacy and favorable safety compared to efavirenz/emtricitabine/tenofovir in treatment-naive HIV-1+ subjects. Presented at: Conference on Retroviruses and Opportunistic Infections 2012. Seattle, WA, USA, 5–8 March 2012 (Abstract 101).
  • De Jesus E, Rockstroh J, Henry K et al. Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir DF “QUAD” compared to ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF in treatment naive HIV-1 infected subjects. Presented at: Conference on Retroviruses and Opportunistic Infections 2012. Seattle, WA, USA, 5–8 March 2012 (Poster 627).
  • Cohen C, Shamblaw D, Ruane P et al. Single-tablet, Fixed-dose regimen of elvitegravir/emtricitabine/tenofovir disoproxil fumarate/GS-9350 achieves a high rate of virologic suppression and GS-9350 is an effective booster. Presented at: Conference on Retroviruses and Opportunistic Infections 2010. San Francisco, CA, USA, 16–19 February 2010.
  • Rodríguez-Nóvoa S, Martín-Carbonero L, Barreiro P et al. Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS 21(1), 41–46 (2007).
  • Capparelli EV, Holland D, Okamoto C et al .; HNRC Group. Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV. AIDS 19(9), 949–952 (2005).
  • Best BM, Letendre SL, Brigid E et al .; CHARTER Group. Low atazanavir concentrations in cerebrospinal fluid. AIDS 23(1), 83–87 (2009).
  • Letendre S. Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. Top. Antivir. Med. 19, 137–142 (2012).
  • Mathias AA, German P, Murray BP et al. Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin. Pharmacol. Ther. 87(3), 322–329 (2010).
  • Brown KC, Paul S, Kashuba AD. Drug interactions with new and investigational antiretrovirals. Clin. Pharmacokinet. 48(4), 211–241 (2009).
  • von Hentig N, Müller A, Rottmann C et al. Pharmacokinetics and tolerability of a combination of indinavir, lopinavir and ritonavir in multiply pretreated HIV-1 infected adults. Eur. J. Med. Res. 11(6), 236–244 (2006).
  • von Hentig N, Müller A, Rottmann C et al. Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen. Antimicrob. Agents Chemother. 51(4), 1431–1439 (2007).
  • Lepist EI, Murray BP, Tong L et al. Effect of cobicistat and ritonavir on proximal renal tubular cell uptake and efflux transporters. Presented at: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2011. Chicago, IL, USA, 17–20 September 2011.

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.